News Releases

News Releases

March 2022

Mar 25th 2022

Takeda’s ALUNBRIG® (brigatinib) approved by China’s NMPA as a new treatment option for patients with ALK-positive non-small cell lung cancer

January 2022

Jan 10th 2022

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

December 2021

Dec 7th 2021

Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting

October 2021

Oct 27th 2021

Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

September 2021

Sep 15th 2021

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

Sep 1st 2021

Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

July 2021

Jul 7th 2021

Takeda Announces China NMPA Acceptance of New Drug Application for Mobocertinib (TAK-788) as a Treatment for Adult Patients with EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

May 2021

May 28th 2021

Marketing Approval Received in Japan for NINLARO® as a Maintenance Therapy after First-Line Treatment for Multiple Myeloma without Prior Stem Cell Transplantation

May 28th 2021

Takeda to Hold Oncology Focused Investor Call on June 8

May 19th 2021

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML

1

2

3

4

5

...

Explore More

Oncology Pipeline

Oncology Pipeline

Discovering and developing innovative therapies to deliver potentially transformative treatments

R&D Approach

R&D Approach

Decades of leadership in Oncology with a diverse and robust pipeline

Leadership Team

Leadership Team

Our Executive Leadership team is designed to drive customer proximity, nimbleness, agility and accountability